- Report
- August 2022
- 120 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Drug Pipelines
- September 2020
- 57 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Report
- January 2021
- 141 Pages
China, Global
From €3000EUR$3,324USD£2,669GBP
- Report
- October 2022
- 307 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,202GBP
- Report
- November 2021
- 620 Pages
Global
From €3867EUR$4,000USD£3,324GBP
- Book
- July 2015
- 328 Pages
Nitazoxanide is a broad-spectrum antiparasitic and antiviral drug used to treat a variety of infectious diseases. It is a nitrothiazolyl salicylamide derivative and is active against protozoa, helminths, and viruses. It is used to treat infections caused by Giardia lamblia, Cryptosporidium parvum, Entamoeba histolytica, and other protozoa, as well as infections caused by nematodes and trematodes. It is also used to treat viral infections such as rotavirus, norovirus, and adenovirus.
Nitazoxanide is available in tablet, suspension, and film-coated tablet forms. It is generally well tolerated, with the most common side effects being nausea, vomiting, and abdominal pain.
Nitazoxanide is marketed by several companies, including Alinia Pharmaceuticals, Inc., Cipla Limited, and Zydus Cadila. Show Less Read more